While CELLSEARCH® remains the only FDA-approved technology for breast cancer CTC enumeration, its dependence on EpCAM-based sorting means that it invariably misses EpCAM-negative CTCs [51,52]. This evidence concerns the gene EPCAM and breast carcinoma.